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Breast cancer is one of the most common malignant 
tumors and a main cause of death from oncological 
diseases in women worldwide. One third, and in eco-
nomically developed countries up to 40% of all cases 
of breast cancer is diagnosed in female patients older 
than 65 years [1]. Young patients account from 2 to 5% 
of all breast cancer population [2–4]. In Ukraine the 
incidence of women for breast cancer increases with 
the age of the patients, reaching maximum in age 
group of 70–74 (148.9 per 100 000 of female popula-
tion), then decreases in age groups of 75–79, 80–84, 
85 years and older where accounts 113.2, 108.5 and 
74.3 per 100 000 of female population respectively. 
The rate of morbidity for breast cancer in age groups 
of 15–19 years, 20–24 years, 25–29 years, 30–
34 years is 0.1, 1.3, 3.2 and 13.7 per 100 000 of female 
population accordingly [3]. As this pathology is rare 
in young women, there are limited studies published 
so far on early breast cancer. Most of them are based 
on the data obtained from the retrospective studies 
on the small number of cases [2, 4].
The early breast cancer is often characterized by the 
presence of a low histological differentiation, high mi-
totic activity, and frequent vascular wall invasion. There 
is no common opinion regarding the age peculiarities 
of Her2/neu, р53, progesterone receptor expression 
[5–8]. There are controversial data on tumor sizes and 
lymph nodes involvement characteristics in patients 
with early breast cancer. M. Colleoni et al. [9] did not 
observe the bigger size of tumor and lymph nodes 
involvement in young female patient in contrast to the 
opinion of a numerous authors who reported it [7, 10]. 
W. Lee et al. [11] demonstrated the absence of diffe-
rences in Her2/neu and p53 expression in cells of breast 
cancer female patients in young and elderly age.
Many investigators pointed out the shorter three- and 
five-years survival of young female patients in comparison 
with elderly females in premenopausal and postmeno-
pausal age. This was the reason to include the age into 
the list of negative prognostic factors in breast cancer. 
Young female patients (35 years old and younger) need 
more chemotherapy compared to the older patients ac-
cording to recommendations of St Gallen consensus.
There are a lot of studies demonstrated that cancer 
patient’s survival depends not only on the stage of the 
disease, but also on the intrinsic biological factors, 
which predispose the characteristics of the tumors. 
The key neoplastic event is the genetic change, which 
leads to uncontrolled cell growth, loss of ability to dif-
ferentiate and disturbance of apoptosis. Situation with 
the molecular-genetic features of the early breast 
cancer is not clear. The changes in estrogen recep-
tor (ER), progesterone receptor (PR), HER-2/neu 
BREAST CANCER IMMUNOHISTOCHEMICAL FEATURES IN YOUNG 
WOMEN WITH BRCA1/2 MUTATIONS
L.M. Zakhartseva1, *, N.G. Gorovenko2, S.V. Podolskaya2, N.F. Anikusko1, 
O.E. Lobanova3, K.A. Pekur1, V.A. Kropelnytskyi1, O.V. Shurygina1
1Kyiv City Oncological Hospital, Kiev 03115, Ukraine
2P.L. Shupyk National Medical Academy of Postgraduate Education, Kiev 04112, Ukraine
3A.A. Bohomolets National Medical University, Kiev 01601, Ukraine
Breast cancer among young women is a rare pathology. In most studies published so far, this patients group is not being analyzed 
separately. Particularities of this pathology require an additional examination of the immunohistochemical and molecular-genetic 
markers of the disease for development of the effective treatment protocols. The mutations of BRCA1/2 are the important factor 
impacting to the disease prognosis along the age of the patient. Aim: To compare the expression of prognostically meaningful im-
munohistochemical markers such as estrogen receptor (ER), progesterone receptor (PR), HER-2, p53, Ki-67, in tumor cells of the 
female patients with breast cancer aged less than 36 depending on the presence or absence of mutations in BRCA1/2 genes. Methods: 
Two hundred forty-eight patients aged less than 36 at the time of diagnosis of breast cancer were examined clinically. Expression 
of ER, PR, HER-2, p53, Ki-67 was determined by indirect immunohistochemical method. Mutations of BRCA1 (185delAG, 
5382insC) and BRCA2 (6174delT) genes were screened using multiplex PCR in 99 patients. Results: Mutations of BRCA1/2 genes 
were found in 9.1% of patients. More aggressive clinical course of the disease was seen in mutations carriers, who had 3-years 
survival of only 55.6%. They did not demonstrated expression of ER, PR, and HER-2 in 88.9% of the cases. Whereas, patients 
without BRCA1/2 mutations did not express ER, PR, and HER-2 in only 42.0% of cases. There were no diffe rences between patients 
with and without mutations in terms of tumor size, presence of metastases in lymph nodes, p53 and Ki-67 expression. Conclusion: 
Presence of BRCA1/2 genes mutations in young women is associated with more aggressiveness of the breast cancer (their 3-years 
survival is 25, 5% less) and absence of the ER, PR, HER-2 receptors, which is unfavorable prognostic factor in terms of hormone 
therapy. These data should be taken into account at chemotherapy planning, especially in patients with early stages of the disease. 
There were no differences between patients with and without BRCA1/2 mutations in terms of tumor size, lymph nodes involvement, 
tumor histology, and p53 and Ki-67 proteins expression.
Key Words: breast cancer, young patients, BRCA1/2 gene mutations, immunohistochemical markers.
Received: August 26, 2009.
*Correspondence:  Fax: +38 (044) 444-68-18
 E-mail: lmz@list.ru
Abbreviations used: ER — estrogene receptor; PCR — polymerase 
chain reaction; PR — progesterone receptor.
Exp Oncol 2009
31, 3, 174–178
Experimental Oncology 31, 174–178, 2009 (September) 175
expression, presence of apoptotic markers, changes 
of indices of proliferative activity are demonstrated 
for breast cancer patients of young age [12]. How-
ever, in spite these characteristics have the clinical 
prognostic value, the protocols of early breast cancer 
diagnostics and treatment urgently need an improve-
ment. A lot of young breast cancer patients received 
too aggressive therapy, whereas, some of them are 
not effectively treated and died prematurely. It is very 
important to have the objective molecular-biologic 
criteria, which could classify the aggressiveness 
of cancer in young patients. The BRCA1/2 mutations 
are very common in young breast cancer patients. 
Thus, it could be assumed that they play an important 
role in carcinogenesis and predetermine the prognosis 
[13]. There are numerous studies linked BRCA1/2 mu-
tations with unfavorable clinical prognosis [14, 15].
BRCA1 (ОМIM 113705) and BRCA 2 (OMIM 600185) 
genes are associated with the prevalence of hereditary 
forms of breast cancer and ovary cancer. The presence 
of germinal mutations of BRCA1 and BRCA2 genes 
increases the risk of the disease in women aged 
50 by 30–50% and in women of 80 years old by 60–
90% [16–18]. The spectrum and frequency of muta-
tions in BRCA1 and BRCA2 genes differs in various 
ethnic groups, therefore, special investigations are 
needed for each population [19–25].
Pathogenesis of BRCA-associated and sporadic 
breast cancer have a lot of differences. It has been 
demonstrated that the size of the breast tumor in car-
riers of BRCA1/2 mutations is greater and the absence 
of regional lymph nodes involvement does not lead 
to the decrease of mortality in carriers of mutated genes. 
Tumors associated with pathologic BRCA-genotype 
have a short duplication period, higher malignancy 
level. According to the majority authorsʼ data, 64–92% 
of tumor cases associated with germinal mutations 
of BRCA1/2 genes do not have receptors of estrogen 
and progesterone; although in some cases patients with 
BRCA2 mutations have paradoxically high expression 
of receptors of steroid hormones. One might consider 
germinal mutations of BRCA genes as molecular-genetic 
markers that have a prognostic value. The development 
of diagnostic algorithm needs receiving sufficient data 
for selecting the most effective treatment regimen 
for young breast cancer female patients. Immunohis-
tochemical and genetic investigations methods acquire 
a particular value currently. The most authors report that 
patients with BRCA1/2 mutations have bigger tumor 
size, more often have metastasis in lymph nodes and 
rarely express ER and PR [26]. The data on Her-2, р53, 
Кі-67 in BRCA1/2 carriers are controversial.
MATERIALS AND METHODS
The investigation was carried out on 248 retrospec-
tive and prospective cases of breast cancer in women 
younger 36 years of age who had been treated at the 
Kiev City Oncological Hospital through 1997–2007, 
which accounted 3.2% of all hospital patients suffer-
ing from this pathology. All patients provided written 
consent to perform the study.
In majority of cases, tumor size was small: Т1 — 
142 cases (57.3%), Т2 — 85 cases (34.3%), Т3 — 
16 cases (6.5%), and Т4 — 5 cases (2.0%). Initial disease 
stages were seen more often: I stage (Т1-2N0M0) — 
46.8%, II stage (Т1-2N0-1M0) — 43.2%. In 127 cases 
patients underwent mastectomy (51.21%), in 83 cas-
es — tissue-sparing operation (33.5%), and 38 patients 
underwent only conservative treatment (15.3%). Verifica-
tion of the diagnosis was done by histology on the core 
biopsy material. In the majority of cases, tumor was dia-
gnosed as an infiltrating ductal carcinoma — 233 cases 
(93.95%), in some cases — infiltrating lobular carcinoma 
(8 cases), medullar (3 cases), giant cellular (1 case), 
squamous cell (1 case) carcinoma, carcinosarcoma 
(1 case), Pedget cancer (1 case). 
Paraffin-embedded tumor sections from 99 pa-
tients were used for immunohistochemical investi-
gation. Indirect immunohistochemical methods with 
monoclonal antibodies against estrogen (clone 1D5), 
progesterone (clone PgR 636), oncoprotein c-erbB-2 
(HER-2/neu), p53, Ki-67 and LSAB and EnVision vi-
sualization system (DAKO) were used. Results were 
assessed by calculating the percentage of tumor cells, 
having stained nucleus with indication of intensivity 
of staining (from 1+ to 3+). In assessing the results 
of reaction with c-erbB-2 antibody we registered the 
presence of intensive membrane staining of the cell 
(from 1+ to 3+). Tumors with detected staining inten-
sivity 2+ and 3+ were considered to be positive. 
In 99 from 248 young patients the mutations 
in BRCA1/2 genes (mutations 5382ins and 185delAG 
in BRCA1 gene, and mutation 6174delТ in BRCA2 gene) 
were screened using DNA isolated from peripheral blood 
or from formalin fixed paraffin-embedded tumor tissue 
sections if the patient was dead at the time of cases 
recruitment. DNA isolation from paraffin-embedded 
sections was performed using method suggested 
by J.L. Bernstein et al. [27]. DNA isolation from peripheral 
blood was performed by a standard method using a com-
mercial test-system DNA Sorb B kit (AmpliSens).
The conditions of DNA amplification and primers 
sequence for detecting of mutations 5382ins and 
185delAG in BRCA1 gene, 6174delT in BRCA2 gene 
were published earlier by P.C. Chan et al. [28]. 
RESULTS AND DISCUSSION 
Mutations of BRCA1/2 have been detected in 9 fe-
male patients from cohort of 99 breast cancer young 
patients (9.1%). Mutation 185delAG in BRCA1 gene was 
detected in 1 patient, mutation 5382ins in BRCA1 gene — 
in 7 patients, mutation 6174delT in BRCA2 gene — 
in 1 patient (Table 1). During the first year after making 
the diagnosis, 4 patients from 9 died (44.4%). The other 
5 young women lived over 3 years, and 3 of them lived 
over 5 years after surgical intervention. Thus, 3-years 
survival reached 55.6%. In the group of living patients, 
T1N0M0 was diagnosed in 3 cased, and T2N1M0 — 
in one case. The size of tumor corresponding to Т1 had 
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44.4% patients with mutations of BRCA1/2 genes, 
Т2 — 34%, Т3 — 21.5%. Lymph nodes metastases were 
detected in 33.3% of patients. One of the died patient 
of this group had the I stage of disease (T1N0M0), the 
second one — II stage without lymph nodes involvement 
(T2N0M0) and only 2 patients had metastases in lymph 
nodes (T2N1M0 и T3N1M0). Thus, probably, aggressive 
course of the disease in those women is not predeter-
mined by the advanced stage of the disease at the mo-
ment of diagnosis but rather by biology of tumor.
Table 1. The results of immunohistochemical studies of young women 
with breast cancer and BRCA1/2 mutations
Ca
se
TN
M
Ty
pe
G
ra
de Immunohistochemical staining Survival 
rateER PR
Her-2/
neu
Ki-
67 p53
Mutation 5382 insC in BRCA1gene
1 T1N0M0 Ductal 
carcinoma
I Neg Neg Neg 90% 60% Alive 
6 years
2 T2N1M0 Lobular 
carcinoma
II Neg Neg Neg 23% 20% Alive 
10 years
3 T1N0M0 Ductal 
carcinoma
II Neg Neg Neg 70% 70% Alive 
3 years
4 T1N0M0 Ductal 
carcinoma
I Pos Pos Neg 40% 20% Alive 
5 years
5 T1N0M0 Ductal 
carcinoma
II Neg Neg Neg 68% 70% Lived less 
than 1 year
6 T2N0M0 Ductal 
carcinoma
II Neg Neg Pos 53% 100% Alive 
4 years
7 T3N1M0 Ductal 
carcinoma
II Neg Neg Pos 75% 100% Lived less 
than 1 year
Mutation 185 del AG in BRCA1 gene
8 T2N1M0 Ductal 
carcinoma
III Neg Neg Neg 60% 100% Lived less 
than 1 year
Mutation 6174 del T in BRCA2 gene
9 T3N0M0 Ductal 
carcinoma
III Neg Neg Pos 40% 90% Lived less 
than 1 year
Notes: In Tables 1, 2, 3: Neg — negative; Pos — positive.
In the group of young age patients without mutations 
in BRCA1/2 genes small size of tumors was predominant: 
Т1 in 46.6% of cases, Т2 — in 44.4%, Т3 — in 8.8%, Т4 — 
in 0.2%.  More than half of the patients (51.6%) did not 
have metastases in lymph nodes and 46% of patients had 
metastases lesions in only one group of lymph nodes, 
2.4% — in two groups. 81.1% of female patients lived 
3 and more years. No differences in histological cancer 
variants in women with mutations of BRCA1/2 and with-
out mutations were found.
Therefore, in cases of similar disease stages 
and similar histological cancer types, the clinical 
course of breast cancer in young age patients ha-
ving BRCA1/2 genes mutations was more aggres-
sive. The index of 3-years survival of patients with 
BRCA1/2 genes mutations was lower by 25.6%.
Estrogen and progesterone receptors expression was 
seen only in one case out of 9 (11.1%) patients with muta-
tions in BRCA1/2 genes (Fig. 1, 2), whereas in patients 
without mutations 57.97% of the cases have an estrogen 
receptor (p < 0.05) and 56.52% of the cases have a pro-
gesterone receptor (p < 0.05) (Table 2, 3).
Table 2. ER and PR status in women with and without BRCA1/2  mutations 
(mean)
Young women < 36 years
With BRCA1/2 
mutations
Without BRCA1/2 
mutations All young women
ER Pos 11.11% 57.97% 49.3%
PR Pos 11.11% 56.52% 47.3%
Neg 88.89% 43.48% 52.7%
Table 3. Estrogen (ER) and progesterone receptor (PgR) status in women 
with and without BRCA1/2 mutations
Immunohis-
tochemical 
staining
Results
Young women < 36 years
With BRCA1/2 
mutations, %
Without BRCA1/2 
mutations, %
All young 
women, %
ER Pos 8.3 ± 7.9 41.4 ± 4.7 38.2 ± 4.4
PR Pos 8.3 ± 7.9 44.1 ±4 .7 40.6 ± 4.4
HER-2 Pos 16.7 ± 10.8 6.3 ± 2.3 7.3 ± 2.3
p 53 > 40% 58.3 ± 14.2 15.3 ± 3.4 19.5 ± 3.6
Ki-67 > 40% 50 ± 14.4 16.2 ± 3.5 19.5 ± 3.6
a
b
Fig. 1. Estrogen receptor expression by breast tumor cells. a, Estrogen 
receptor has a nuclear expression in the majority of the tumor cells. 
b, Case with negative estrogen receptor expression. Immunohistoche-
mistry staining, visualisation system EnVision, chromogene DAB, X 400
Fig. 2. Progesteron receptor has a nuclear expression in the 
majority of the tumor cells. Immunohistochemistry staining, 
visualisation system EnVision, chromogene DAB, X 400
Overexpression of oncoprotein HER2/neu was 
observed in 3 cases from 9 in patients with mutation 
of BRCA1/2 genes (33.3%) and in 13.85% in breast can-
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cer women without mutations of those genes (Fig. 3). 
Protein p53 expression in more than 50% of tumors cells 
was observed in 6 cases from 9 in case of the presence 
of BRCA1/2 genes mutation (66.7%) and in 50% of fe-
male patients without mutations of those genes (Fig. 4). 
Mitotic tumor activity in patients of the both groups was 
insignificantly different: high mitotic index 57.1% was 
in mutated breast cancer women and in 50% cases 
in unmutated breast cancer patients (Fig. 5).
Fig. 3. HER-2/neu (C-erB-2 oncoprotein) (2+) membrane 
expression in the tumor cells. Immunohistochemistry staining, 
visualisation system EnVision, chromogene DAB, X 400
Fig. 4. P53 protein was expressed by all tumor cells. Immunohistoche-
mistry staining, visualisation system EnVision, chromogene DAB, X 400
Fig. 5. Ki-67 protein was expressed in 70% of the tumor cells. 
Immunohistochemistry staining, visualisation system EnVision, 
chromogene DAB, X 400
In conclusion, BRCA1/2 genes mutations were 
found in 9.1% of the patients. No differences in histo-
logical cancer variants and disease stages in women 
with mutations of BRCA1/2 and without mutations were 
found. The presence of mutations in BRCA1/2 genes 
in young women is associated with more aggressive 
course of the breast cancer and absence of the pro-
gesterone and estrogene receptors (see Fig. 1), which 
is unfavorable prognostic factor.
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